The temporal and spatial distribution of macrophage subpopulations during arteriogenesis

Current Vascular Pharmacology

Volumn 11, Issue 1, 2013, Pages 5-12

  Troidl, C ^a   Jung, G ^b,c   Troidl, K ^b,c   Hoffmann, J ^a   Mollmann H ^a   Nef, H ^a   Schaper, W ^b   Hamm, C W ^a   Schmitz Rixen, T ^c  

^a Kerckhoff Heart and Thorax Center   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Activation type; Arteriogenesis; Collateral artery; Macrophages

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTERY OCCLUSION; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MACROPHAGE ACTIVATION; MALE; MONONUCLEAR CELL; NONHUMAN; PERFUSION; RAT; SHEAR STRESS; VASCULAR BIOLOGY; VASCULAR REMODELLING;

EID: 84873120774     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016113804547629     Document Type: Article

References (40)

1. Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003; 23: 1143-51.
2. Schaper W, Pipp F, Scholz D, et al. Physical Forces and their Translation into Molecular Mechanisms, in Arteriogenesis, Schaper WS, Editor. Kluwer Academic Publishers: Boston, Dordrecht, London, 2004.
3. Schierling W, Troidl K, Troidl C, Schmitz-Rixen T, Schaper W, Eitenmüller IK. The role of angiogenic growth factors in arteriogenesis. J Vasc Res 2009; 46: 365-74.
4. Zbinden S, Zbinden R, Meier P, Windecker S, Seiler C. Safety and efficacy of subcutaneous-only granulocyte-macrophage colonystimulating factor for collateral growth promotion in patients with coronary artery disease. J Am Coll Cardiol 2005; 46: 1636-42.
5. Meier P, Gloekler S, de Marchi SF, et al. Myocardial salvage through coronary collateral growth by granulocyte colonystimulating factor in chronic coronary artery disease: a controlled randomized trial. Circulation 2009; 120: 1355-63.
6. van Royen N, Piek JJ, Legemate DA, et al. Design of the STARTtrial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial. Vasc Med 2003; 8: 191-6.
7. van Royen N, Piek JJ, Schaper W, Fulton WF. A critical review of clinical arteriogenesis research. J Am Coll Cardiol 2009; 55: 17-25.
8. van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 2001; 49: 543-53.
9. Seiler C, Pohl T, Wustmann K, et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104: 2012-7.
10. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998; 101: 40-50.
11. Schaper J, König R, Franz D, Schaper W. The endothelial surface of growing coronary collateral arteries. Intimal margination and diapedesis of monocytes. A combined SEM and TEM study. Virchows Arch A Pathol Anat Histol 1976; 370: 193-205.
12. Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004; 95: 449-58.
13. Ziegelhoeffer T, Fernandez B, Kostin S, et al. Bone marrowderived cells do not incorporate into the adult growing vasculature. Circ Res 2004; 94: 230-8.
14. Khmelewski E, Becker A, Meinertz T, Ito WD. Tissue resident cells play a dominant role in arteriogenesis and concomitant macrophage accumulation. Circ Res 2004; 95: E56-64.
15. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-86.
16. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
17. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-64.
18. Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004; 4: 432-44.
19. Gratchev A, Guillot P, Hakiy N, et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol 2001; 53: 386-92.
20. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73: 209-12.
21. Eitenmuller I, Volger O, Kluge A, et al. The range of adaptation by collateral vessels after femoral artery occlusion. Circ Res 2006; 99: 656-62.
22. Limbourg A, Korff T, Napp LC, Schaper W, Drexler H, Limbourg FP. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc 2009; 4: 1737-46.
23. Heil M, Ziegelhoeffer T, Wagner S, et al. Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res 2004; 94: 671-7.
24. Micklem K, Rigney E, Cordell J, et al. A human macrophageassociated antigen (CD68) detected by six different monoclonal antibodies. Br J Haematol 1989; 73: 6-11.
25. Buechler C, Ritter M, Orsó E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro-and antiinflammatory stimuli. J Leukoc Biol 2000; 67: 97-103.
26. Buschmann IR, Hoefer IE, van Royen N, et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 2001; 159: 343-56.
27. van Royen N, Hoefer I, Böttinger M, et al. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res 2003; 92: 218-25.
28. van Royen N, Hoefer I, Buschmann I, et al. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. Cardiovasc Res 2003; 57: 178-85.
29. Buschmann I, Heil M, Jost M, Schaper W. Influence of inflammatory cytokines on arteriogenesis. Microcirculation 2003; 10: 371-9.
30. Mosser DM, Zhang X. Activation of murine macrophages. Curr Protoc Immunol 2008; Chapter 14: Unit 142.
31. Hatakeyama S, Iwabuchi K, Ogasawara K, Good RA, Onoé K. The murine c-fgr gene product associated with Ly6C and p70 integral membrane protein is expressed in cells of a monocyte/macrophage lineage. Proc Natl Acad Sci USA 1994; 91: 3458-62.
32. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-47.
33. Voskuil M, Hoefer IE, van Royen N, et al. Abnormal monocyte recruitment and collateral artery formation in monocyte chemoattractant protein-1 deficient mice. Vasc Med 2004; 9: 287-92.
34. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 2001; 81: 999-1030.
35. Bhattacharyya S, Brown DE, Brewer JA, Vogt SK, Muglia LJ. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 2007; 109: 4313-9.
36. Patsouris D, Neels JG, Fan W, Li PP, Nguyen MT, Olefsky JM. Glucocorticoids and thiazolidinediones interfere with adipocytemediated macrophage chemotaxis and recruitment. J Biol Chem 2009; 284: 31223-35.
37. Yao J, Wang JY, Lai MG, et al. Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed Bifidobacterium longum. Mol Pharm 2011; 8: 488-97.
38. Ngeow WC, Atkins S, Morgan CR, et al. A comparison between the effects of three potential scar-reducing agents applied at a site of sciatic nerve repair. Neuroscience 2011; 181: 271-7.
39. Villalta SA, Rinaldi C, Deng B, Liu G, Fedor B, Tidball JG. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet 2011; 20: 790-805.
40. Martinez FO, Helming L, and Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-83.